For the quarter ending 2026-03-31, BTAI has $34,025K in assets. $139,568K in debts. $17,180K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 17,180 | 36,176 | 17,435 | |
| Restricted cash | 0 | 1,144 | 1,140 | |
| Accounts receivable, net | 216 | 0 | 17 | |
| Inventory | 500 | 459 | 506 | |
| Prepaid expenses | 3,945 | 5,690 | 5,150 | |
| Other current assets | 12,067 | 934 | 995 | |
| Total current assets | 33,908 | 44,403 | 25,243 | |
| Property and equipment, net | 117 | 249 | 324 | |
| Operating lease right-of-use assets | 0 | 140 | 222 | |
| Other assets | - | 0 | - | |
| Total assets | 34,025 | 44,792 | 25,789 | |
| Accounts payable | 16,247 | 16,276 | 16,692 | |
| Accrued expenses | 6,388 | 4,363 | 5,090 | |
| Current portion of long-term debt | 22,431 | 16,823 | 11,216 | |
| Other current liabilities-Related Party | 178 | 122 | 122 | |
| Other current liabilities-Nonrelated Party | 9,750 | 220 | 256 | |
| Total current liabilities | 54,994 | 37,804 | 33,376 | |
| Long-term portion of operating lease liabilities | - | 0 | - | |
| Derivative liabilities | 6,716 | 3,605 | 2,611 | |
| Long-term debt | 77,858 | 92,302 | 97,469 | |
| Total liabilities | 139,568 | 133,711 | 133,456 | |
| Common stock, 0.001 par value, 200,000 shares authorized as of march 31, 2026 and december 31, 2025 27,075 and 22,328 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 27 | 73 | 60 | |
| Additional paid-in-capital | 627,215 | 618,557 | 568,911 | |
| Accumulated deficit | -732,785 | -707,549 | -676,638 | |
| Total stockholders' (deficit) equity | -105,543 | -88,919 | -107,667 | |
| Total liabilities and stockholders' (deficit) equity | 34,025 | 44,792 | 25,789 | |
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)